Analysis of the standard dosage and usage of ensifentrine-Ohtuvayre and patient medication precautions

Ensifentrine (Ensifentrine, trade nameOhtuvayre) is a new dual mechanism bronchodilation It is an agent that has both phosphodiesterase inhibitory effect and β2 receptor agonism. It is mainly used to relieve respiratory symptoms in patients with chronic obstructive pulmonary disease (COPD). Its mechanism of action is unique. It can not only dilate the bronchi and improve airflow limitation, but also reduce airway inflammatory response, thus showing potential advantages in improving patients' respiratory function and quality of life.

The standard administration method for Ohtuvayre is as an inhaled solution, administered via aerosolization. The usual adult dose is 3 mg/2.5 ml twice daily, approximately 12 hours apart. A nebulizer is required during inhalation to ensure that the medicinal solution is fully atomized to achieve the best lung absorption effect. Before use, you should carefully check whether the medicinal solution is clear and particle-free, and ensure that the atomizer and related equipment are clean to avoid drug contamination or reduction in delivery efficiency.

During the use of Ohtuvayre, patients should pay attention to inhaling on time and in accordance with the amount, and do not increase the dose or change the frequency of administration without authorization to prevent increased risks of cardiovascular or nervous system side effects. Keep your mouth clean before and after inhaling the drug, and avoid eating large amounts of food immediately to prevent the drug from irritating the throat or causing discomfort. For patients with severe cardiovascular disease, arrhythmia or hypertension, they should be used under the guidance of a doctor, and changes in heart rate and blood pressure should be monitored regularly.

In terms of efficacy monitoring, patients should pay close attention to the improvement of respiratory symptoms, such as shortness of breath, cough and changes in sputum volume, and regularly review lung function indicators. If obvious palpitations, chest pain, dizziness or other discomfort occur, you should stop taking the medicine immediately and seek medical advice. Overall, the standardized usage and safe use measures of Ohtuvayre are of great significance to improving the therapeutic effect and reducing adverse reactions. Patients must strictly follow the doctor's instructions for inhalation treatment.

Reference materials:https://www.drugs.com/